GastroBot: Artificial Intelligence Applied to Bowel Preparation
NCT ID: NCT05836064
Last Updated: 2023-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
388 participants
INTERVENTIONAL
2024-01-01
2025-04-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
GastroBot is a new technology based on artificial intelligence that allows, through a software bot, to carry out a personalized follow-up of the patient's bowel cleansing, advising the patient to overcome contingencies that arise with the preparation, which in other circumstances could lead to the failure of it. The primary aim of this study is to determine the improvement in bowel preparation after GastroBot assistance compared with the traditional explanation. As a secondary aim, this study also pursues to determine adenoma and polyp detection rates (ADR and PDR, respectively), bowel preparation agents' tolerance, and GastroBot functionality.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Therefore, focusing on improving the ADR is mandatory to reduce the incidence of CRC. Many techniques have been described for this purpose, like improving endoscopists' education and training, split-dosing bowel preparations, withdrawal time \>9 minutes and right colon second view, high-definition white light endoscopy, Endocuff vision, G-EYE scope or Artificial Intelligence. (2, 4) However, all these techniques have in common the need for optimal visualization of the intestinal mucosa, which depends on bowel cleansing. (3,4)
Problem It is estimated that about 20% of colonoscopies have inadequate preparation. (5) This is associated with lengthy procedures and less detection of adenomas, reduces the screening intervals, and increases the costs and risks of complications. This causes frustration for the patient and physician with medico-legal conflicts. (6) The ideal cleansing method must be safe, well-tolerated, and effective. However, none of the current options fulfills these characteristics. The main cause of inappropriate cleansing (80% of cases) is a failure to adequately follow preparation instructions and mostly because of intolerance to the oral solution. (7,8)
Several strategies have been proposed to improve the quality of bowel preparation. As in other fields, mobile healthcare Apps have been developed to increase adherence to bowel preparation agents, improving quality bowel preparation. However, adherence to mobile healthcare Apps is also a quality criterion and a pending problem to solve with this new technology. Also, as with any mobile App, mobile healthcare Apps must be compatible with specific devices. GastroBot is a new technology based on artificial intelligence that allows, through a software bot, to carry out a personalized follow-up of the patient's bowel cleansing, advising the patient to overcome contingencies that arise with the preparation, which in other circumstances could lead to the failure of it.
Aim The primary aim of this study is to determine the improvement in bowel preparation after GastroBot assistance compared with the traditional explanation. As a secondary aim, this study also pursues to determine adenoma and polyp detection rates (ADR and PDR, respectively), bowel preparation agents' tolerance, and GastroBot functionality.
MATERIALS AND METHODS
Study design Study type. The following is a cross-section simple-blind and single-center controlled randomized trial. Two groups will be established: the GastroBot-assisted bowel preparation (GB-group) and the conventional-assisted bowel preparation (C-group) group.
Setting. It will be performed in consecutive patients with bowel preparation agents indication before undergoing a colonoscopy with cecal intubation at the Instituto de Gastroenterología y Endoscopía de Avanzada (IGEA), Hospital de la Asociación Médica (HAM) "Dr. Felipe Glasman" Bahía Blanca, Buenos Aires province, Argentina. The study protocol and consent form have been approved by the Institutional Review Board (IRB) and will be conducted according to the declaration of Helsinki. Patients will sign an informed consent.
Intervention A clinical coordinator will be responsible for patients' randomization. Patients from both study groups will receive the same type of preparation with polyethylene glycol in split dose, establishing the intake time according to three-time segments (8-11 am, 11-2 pm, 2-4 pm). The C-group will receive the instructions in writing without prior personalized advice. The GB group will receive the instructions through the WhatsApp application, guided by the software bot with multiple and personalized alternative instructions according to results. The endoscopist will perform the endoscopy by assessing primary and secondary endpoints, blinded to the patient's study group.
Sample size Considering the proportion of insufficient BBPS (\<6) among the App-group (7.7%) vs. controls (16.9%) described by Walter B et al. (2021), a sample size of 194 cases per study group was estimated to determine a two-sided difference on BBPS between GB-group vs. C-group with an 80% statistical power.
Statistical analysis Baseline characteristics will be compared between the case and control group using Chi-square o Fisher test for categorical variables and Mann-Whitney U or Student's t-test for continuous variables. A P value of less than 0.05 will be considered statistically significant. All the statistical analysis will be performed using the latest version of the statistical program R (R Foundation for Statistical Computing; Vienna, Austria).
Limitations The protocol will be performed in only one center and by six endoscopists. It is a simple blind study. The patients will know they are using (or not) a novel instrument to increase bowel preparation quality.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GastroBot-assisted bowel preparation group (GB-group)
Adult patients with no surgical high-risk comorbidities and colonoscopy indications for screening, surveillance, or diagnosis who are undergoing a colonoscopy. GastroBot assisted with the polyethylene glycol bowel preparation: patients will receive the instructions through the WhatsApp application, being guided by the software bot with multiple and personalized alternative instructions according to results.
GastroBot
An artificial intelligence-developed and WhatsApp-based software bot. It will send the instructions to the patient through the WhatsApp application, guided by the software bot with multiple and personalized alternative instructions according to results.
Conventional-assisted bowel preparation group (C-group).
Adult patients with no surgical high-risk comorbidities and colonoscopy indications for screening, surveillance, or diagnosis who are undergoing a colonoscopy. The patients received bowel polyethylene glycol bowel preparation instructions in writing without prior personalized advice.
Conventional explanation
Patients will receive in writing detailed explanation about bowel preparation with polyethylene glycol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GastroBot
An artificial intelligence-developed and WhatsApp-based software bot. It will send the instructions to the patient through the WhatsApp application, guided by the software bot with multiple and personalized alternative instructions according to results.
Conventional explanation
Patients will receive in writing detailed explanation about bowel preparation with polyethylene glycol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Who agrees to participate in the study and can understand and provide written informed consent.
* Any colonoscopy indication: colorectal neoplasia screening, surveillance of colon pre-existing diseases, or diagnostic approach in symptomatic patients.
* Smartphone owners (any device) and WhatsApp users, independence of local or international mobile phone provider.
Exclusion Criteria
* Patients with difficulty understanding instructions for bowel preparation or not being able to use WhatsApp.
* History of diabetes mellitus with insulin therapy, heart disease, kidney, liver, or severe metabolic disorder.
* Phenprocoumon therapy or severe uncontrolled coagulopathy
* Pregnancy and lactation
* Prior history of colon resection, ileostomy, or colostomy
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institute of Gastroenterology and Advance Endoscopy
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Manuel Valero
Medical director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Manuel Valero, MD
Role: PRINCIPAL_INVESTIGATOR
Instituto de Gastroenterología y Endoscopía de Avanzada (IGEA)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Gastroenterology and Advanced Endoscopy (IGEA)
Bahía Blanca, Buenos Aires, Argentina
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Gubbiotti A, Spadaccini M, Badalamenti M, Hassan C, Repici A. Key factors for improving adenoma detection rate. Expert Rev Gastroenterol Hepatol. 2022 Sep;16(9):819-833. doi: 10.1080/17474124.2022.2128761. Epub 2022 Oct 14.
Rex DK, Schoenfeld PS, Cohen J, Pike IM, Adler DG, Fennerty MB, Lieb JG 2nd, Park WG, Rizk MK, Sawhney MS, Shaheen NJ, Wani S, Weinberg DS. Quality indicators for colonoscopy. Gastrointest Endosc. 2015 Jan;81(1):31-53. doi: 10.1016/j.gie.2014.07.058. Epub 2014 Dec 2. No abstract available.
Hassan C, Spadaccini M, Iannone A, Maselli R, Jovani M, Chandrasekar VT, Antonelli G, Yu H, Areia M, Dinis-Ribeiro M, Bhandari P, Sharma P, Rex DK, Rosch T, Wallace M, Repici A. Performance of artificial intelligence in colonoscopy for adenoma and polyp detection: a systematic review and meta-analysis. Gastrointest Endosc. 2021 Jan;93(1):77-85.e6. doi: 10.1016/j.gie.2020.06.059. Epub 2020 Jun 26.
Ness RM, Manam R, Hoen H, Chalasani N. Predictors of inadequate bowel preparation for colonoscopy. Am J Gastroenterol. 2001 Jun;96(6):1797-802. doi: 10.1111/j.1572-0241.2001.03874.x.
Aganiants EK. [Changes in the impulse activity of cerebral cortex neurons upon inhalation of ether in different concentrations]. Biull Eksp Biol Med. 1968 Sep;66(9):45-8. No abstract available. Russian.
Jansen SV, Goedhard JG, Winkens B, van Deursen CT. Preparation before colonoscopy: a randomized controlled trial comparing different regimes. Eur J Gastroenterol Hepatol. 2011 Oct;23(10):897-902. doi: 10.1097/MEG.0b013e32834a3444.
Juluri R, Eckert G, Imperiale TF. Polyethylene glycol vs. sodium phosphate for bowel preparation: a treatment arm meta-analysis of randomized controlled trials. BMC Gastroenterol. 2011 Apr 14;11:38. doi: 10.1186/1471-230X-11-38.
Hassan C, East J, Radaelli F, Spada C, Benamouzig R, Bisschops R, Bretthauer M, Dekker E, Dinis-Ribeiro M, Ferlitsch M, Fuccio L, Awadie H, Gralnek I, Jover R, Kaminski MF, Pellise M, Triantafyllou K, Vanella G, Mangas-Sanjuan C, Frazzoni L, Van Hooft JE, Dumonceau JM. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2019. Endoscopy. 2019 Aug;51(8):775-794. doi: 10.1055/a-0959-0505. Epub 2019 Jul 11.
Walter B, Frank R, Ludwig L, Dikopoulos N, Mayr M, Neu B, Mayer B, Hann A, Meier B, Caca K, Seufferlein T, Meining A. Smartphone Application to Reinforce Education Increases High-Quality Preparation for Colorectal Cancer Screening Colonoscopies in a Randomized Trial. Clin Gastroenterol Hepatol. 2021 Feb;19(2):331-338.e5. doi: 10.1016/j.cgh.2020.03.051. Epub 2020 Mar 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IGEA01-2023
Identifier Type: -
Identifier Source: org_study_id